Ultragenyx Pharmaceutical Independent Director Matthew Fust Sells 45% Of Holding
Ultragenyx Pharmaceutical Independent Director Matthew Fust Sells 45% Of Holding
Some Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shareholders may be a little concerned to see that the Independent Director, Matthew Fust, recently sold a substantial US$620k worth of stock at a price of US$50.88 per share. That's a big disposal, and it decreased their holding size by 45%, which is notable but not too bad.
独立董事马修·福斯特最近以每股50.88美元的价格出售了价值62万美元的大量股票,一些Ultragenyx Pharmaceutical Inc.(纳斯达克股票代码:RARE)的股东可能会有点担心。这是一笔巨额出售,它使他们的持股规模减少了45%,这值得注意,但还不错。
The Last 12 Months Of Insider Transactions At Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical 过去 12 个月的内幕交易
Notably, that recent sale by Matthew Fust is the biggest insider sale of Ultragenyx Pharmaceutical shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$47.66. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).
值得注意的是,马修·富斯特最近的出售是我们去年对Ultragenyx Pharmaceutical股票的最大一次内幕出售。因此,我们知道一位内部人士以目前的47.66美元左右的股价出售了股票。尽管内幕抛售是负面的,但对我们来说,如果以较低的价格出售股票,则负面影响更大。在这种情况下,大甩卖是在当前价格左右进行的,因此还不错(但仍然不是积极的)。
Insiders in Ultragenyx Pharmaceutical didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
去年,Ultragenyx Pharmaceutical的内部人士没有购买任何股票。你可以在下面看到过去 12 个月内幕交易(公司和个人)的直观描述。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240313/0-4575b9c770cabc9d7b0b2d96460cdeeb-0-1f23fbf8e66cbe009ade7db5d3eb58fe.png/big)
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Does Ultragenyx Pharmaceutical Boast High Insider Ownership?
Ultragenyx Pharmaceutical 是否拥有很高的内部所有权?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Ultragenyx Pharmaceutical insiders own 3.9% of the company, currently worth about US$155m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
查看公司的内部持股总量可以帮助你了解他们是否与普通股股东保持一致。我们通常希望看到相当高的内部所有权水平。Ultragenyx制药内部人士拥有该公司3.9%的股份,根据最近的股价,目前价值约1.55亿美元。我喜欢看到这种程度的内部所有权,因为它增加了管理层考虑股东最大利益的机会。
So What Does This Data Suggest About Ultragenyx Pharmaceutical Insiders?
那么这些数据对Ultragenyx制药业内部人士有什么启示呢?
Insiders sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. It is good to see high insider ownership, but the insider selling leaves us cautious. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 3 warning signs with Ultragenyx Pharmaceutical and understanding them should be part of your investment process.
内部人士最近出售了股票,但他们一直没有买入。展望过去的十二个月,我们的数据并未显示任何内幕买盘。看到较高的内部所有权是件好事,但内幕抛售使我们持谨慎态度。因此,虽然了解内部人士在买入或卖出方面的所作所为很有帮助,但了解特定公司面临的风险也很有帮助。在投资风险方面,我们已经确定了Ultragenyx Pharmaceutical的3个警告信号,并了解它们应该成为您投资过程的一部分。
Of course Ultragenyx Pharmaceutical may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,Ultragenyx Pharmaceutical可能不是最好的买入股票。因此,您可能希望看到这个免费的高质量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。